The Science Behind Dual Pathway Inhibition in CAD/PAD

The Science Behind Dual Pathway Inhibition in CAD/PAD is organized by Paradigm Medical Communications, LLC.

Release Date: April 28, 2023
Expiration Date: April 28, 2024

Program Overview:
Antiplatelet therapy has been the long-running standard of care for patients with stable CAD and PAD, yet it is often insufficient to protect against secondary cardiovascular events. Can the addition of antithrombotic therapy help bridge this gap? Join our expert faculty as they delve into the latest science on dual pathway inhibition.

Learning Objectives:
Upon completion of this activity, participants should be able to:
• Describe key factors in the pathophysiology of atherosclerotic disease that elucidate the role of dual pathway inhibition

0.3 AMA PRA Category 1 Credit™ | 0.3 Contact Hours | 0.0 CEU